A rapidly ageing population and its susceptibility to chronic diseases are driving to a rise in China’s total healthcare spending. With a total of approximately EUR 533 billion expenditure in 2016, China’s healthcare market remains one of the most promising markets worldwide.
In addition, China’s latest reforms, framed in the 13th Five Year Plan, are drawing the attention to improving the population’s health. Promoting a healthy lifestyle, optimising and diversifying health services as well as improving health security are the core elements of the new regulations.
Although a wide range of opportunities, competition in this sector can be fierce. Yet, if well prepared, EU SMEs specialised in pharmaceutical products, medical devices and healthcare services may succeed in the market.
After the 2014 “Healthcare Sector in China” report, this update takes into account the recent policy changes and outlines the current healthcare market in China providing a full understanding in terms of market background, regulatory policies, key players and ways to overcome the challenges.
Furthermore, it outlines the key factors an EU SME should consider to prosper in this vast and competitive market.
Key Contents
Sector Overview
Healthcare Providers
Pharmaceutical. Medical Device & Healthcare Service Providers Overview
Market Information Regulatory Policies Key Players Traditional Chinese Medicine (TCM)
Market Information Regulatory Policies Key Players Distribution Channels Future Outlook
Private Healthcare Institutions Healthcare IT (HIT) Rehabilitation Service Providers Elderly Care Providers
Opportunities for SMEs
Challenges for SMEs
Annexes
Interested in other reports related to healthcare in China? Check the latest report on “The Medical Devices Market in China“.
This report was published during the EU SME Centre in China Phase II (2014-2020), which was funded by the European Union (ICI+/2014/346-276). The report was drafted in collaboration with external creators, who worked under service agreements with the Consortium running the EU SME Centre Phase II. The copyrights and intellectual property of this publication belong to the Consortium partner China-Britain Business Council. The latter was authorised by and acted on behalf of the Consortium running EU SME Centre in China Phase II. The China-Britain Business Council, which is currently part of the Consortium running the EU SME Centre in China Phase III, has granted the rights of use of this report to the current Consortium. The report is therefore re-published and made available during the EU SME Centre Phase III.
